In our study, we found that teniposide has a potential therapeutic effect on A-HCC by down-regulating the expression of A-HCC core genes (DNMT1 and EZH2), thereby reversing the malignant degree of A-HCC and improving the prognosis. The gene discussed is EZH2; the disease is hepatocellular carcinoma.